Molecular Characterization of Clinical Strains of Extended-Spectrum Βeta-Lactamases-Producing Klebsiella Pneumoniae Isolated in A Tertiary Hospital in Dakar-Senegal

Author(s): Komla Mawunyo Dossouvi, Bissoume Sambe Ba, Gora Lo, Abdoulaye Cissé, Awa Ba-Diallo, Issa Ndiaye, Assane Dieng, Serigne Mbaye Lo Ndiaye, Cheikh Fall, Alioune Tine, Farba Karam, Habsa Diagne-Samb, Ousmane Sow, Safietou Ngom-Cisse, Halimatou Diop-Ndiaye, Gnatoulma Katawa, Coumba Toure-Kane, Aïssatou Gaye-Diallo, Simplice Damintoti Karou, Souleymane Mboup, Cheikh Saad Bouh Boye, Abdoulaye Seck, Makhtar Camara

Klebsiella pneumoniae (K. pneumoniae) isolates are often multidrug-resistant (MDR) and clones producing extended-spectrum beta-lactamases (ESBL) are increasingly reported all over the world. This study aimed to determine drug-susceptibility profiles and characterize ESBL genes in clinical strains of K. pneumoniae in an university teaching hospital of Dakar. Sixty-six ESBL-producing K. pneumoniae strains were selected for this study and subjected to the Kirby-Bauer disk diffusion method and standard polymerase chain reaction (PCR) for the screening of major ESBL genes (blaCTX-M, blaCTX-M-9, blaCTX-M-15, blaCTX-M-25, blaOXA-1, blaTEM, blaSHV).

All isolates were resistant to ampicillin, ticarcillin, amoxicillin/clavulanic acid combination, cefalotin, cefotaxime, ceftazidime and cefepime, while 60% (40/66) of them were resistant to fosfomycin. Amikacin, ertapenem and imipenem remained effective with respective sensitivity rate of 77.3% (51/66), 75.8% (50/66) and 100% (66/66). blaCTX-M (64/66; 97%) with its variant blaCTX-M-15 (63/66; 95.5%) were the most prevalent ESBL genes; followed by blaTEM (58/66; 87.9%), blaOXA-1 (47/66; 71.2%) and blaSHV (31/66; 47%). Sixty-four isolates out of 66 (97%) of isolates carried at least 2 ESBL genes and the most prevalent ESBL gene combinations were (blaCTX-M-15 + blaOXA-1 + blaTEM) (24/66; 36.4%) and (blaCTX-M-15 + blaTEM + blaOXA-1 + blaSHV) (18/66; 27.3%).

Cephalosporins, quinolones and aminoglycosides (except amikacin) would no l

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved